Medicare GLP-1 Bridge prior authorization denied: what to check and what to do
A denied PA isn’t always the end of the road — under the Bridge, several common denial causes are fixable paperwork or routing issues, not final judgments about you. Here’s a calm checklist grounded in what CMS has published, plus where the real appeal rights live if your situation actually belongs on the Part D side.
First, understand who denied it
Bridge prior authorizations don't go to your Part D plan: in 2026, CMS uses a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies. [v2-4] Your prescriber submitted the PA (electronically or by fax) with the prescription. [v2-11] So the first conversation is with your prescriber's office — they submitted it, and they received the response.
The fixable-cause checklist
Go through these with your prescriber's office. Each one maps to a published rule, and several are pure paperwork.
1. Wrong formulation. Zepbound is covered only as the KwikPen — CMS states the single-dose vial and single-dose pen formulations will not be available. [v2-6] A PA or prescription written for Zepbound vials points at a product the Bridge doesn't cover; ask your prescriber whether re-prescribing the KwikPen formulation fits your care. [v2-6] Foundayo and Wegovy are covered in all formulations. [v2-6]
2. The attestation didn't use your therapy-initiation status. The clinical criteria are met "at the time of GLP-1 therapy initiation" — including for people who started before Part D enrollment or before the Bridge launched. [v2-8] CMS's own example: started September 2024 at BMI 37, applying July 2026 at BMI 34 — the doctor attests on the initiation-time 37. [v2-8] If the PA reflected your current BMI instead of your initiation-time status, that's worth a corrected resubmission conversation with your prescriber. [v2-8]
3. An indication routed you to Part D. If the records show type 2 diabetes, moderate-to-severe OSA, or noncirrhotic MASH, CMS says GLP-1s for those indications are covered through Part D — and that makes you ineligible for the Bridge even if you meet the clinical criteria. [v2-9] This one isn't a paperwork fix; it means your coverage path is your Part D plan, which has its own PA and appeal process (see below).
4. Plan type. The Bridge requires a standalone PDP or an MA-PD coordinated care plan (HMO/HMOPOS/local or regional PPO); SNPs, EGWPs, and LI NET can participate, while PFFS, 1876 cost, HCPP, PACE, fallback, and religious fraternal plans cannot unless you're also in a standalone PDP. [v2-10] Our plan-types guide walks through this.
5. Criteria genuinely not met, or timing. The three published tiers (BMI ≥35; ≥30 + listed condition; ≥27 + listed condition) are attested by the prescriber. [v2-7] Also note PAs weren't accepted before July 1, 2026, and the prescriber must not be on the Preclusion List (they don't need to be Medicare-enrolled). [v2-11]
Who to call
- Your prescriber's office — they own the PA and any resubmission. [v2-11]
- Prescriber hotline (for your doctor's office to use): 855-273-0102, Monday–Friday 8am–7pm ET. [v2-12]
- You: 1-800-MEDICARE or Medicare.gov/glp1bridge. [v2-12]
One honest note: the CMS pages we cite describe the PA submission process but do not spell out a formal appeals procedure for Bridge denials. [v2-11] We won't invent one — ask 1-800-MEDICARE what review options exist for your specific denial, and treat anything a third party tells you about promised overturns with skepticism. [v2-12]
If your situation is actually a Part D matter
If the denial reason is that your indication belongs on the Part D side (diabetes, moderate-to-severe OSA, noncirrhotic MASH) [v2-9], then the decision that matters is your Part D plan's — and Part D coverage determinations carry real appeal rights. An unfiled appeal recovers nothing; we can't promise any outcome, but we can help you put your best case on paper.
This page summarizes public CMS guidance as of July 2026 and is general information, not medical or insurance advice. We can't and don't promise any particular outcome on any PA or appeal. Program details are set by CMS and may change — confirm current rules on the official CMS Medicare GLP-1 Bridge page and at Medicare.gov/glp1bridge. [v2-12]
Frequently asked questions
Can I appeal a Bridge PA denial the way I'd appeal a Part D denial?
The CMS pages we cite don't describe a Bridge-specific appeals procedure. [v2-11] Ask 1-800-MEDICARE about review options for your denial; if your case actually routes through Part D, that path has its own established appeal process. [v2-12] [v2-9]
The denial says my drug isn't covered — but Zepbound is on the list?
Check the formulation: only the Zepbound KwikPen is covered; single-dose vials and pens are not. [v2-6]
My BMI today is below the threshold. Is resubmission pointless?
Not necessarily — criteria are judged at therapy initiation, and CMS's own example qualifies someone whose BMI fell from 37 to 34. [v2-8] Discuss your initiation-time records with your prescriber. [v2-8]
Should my doctor's office call somewhere?
There's a dedicated prescriber hotline: 855-273-0102, Mon–Fri 8am–7pm ET. [v2-12]
Part D denial in the mix? Build your appeal free
IntelClaim’s free diagnosis tells you what you’re holding, whether it’s worth fighting, and which path fits — then helps you build the appeal or PA request. Purpose-built, self-help, you stay in control.
IntelClaim is a self-help tool — not legal, medical, or insurance advice — and does not guarantee any particular outcome. Information on this site is general and may not reflect the rules of your specific plan or state. Always read your own denial letter, plan documents, and the deadlines that apply to you, and consider professional advice for your situation. No PHI is collected on this marketing site.